

Date: May 27, 2013

To,

The Managing Director,
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

The Managing Director,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra East, Mumbai 400 051

Subject: Notice of Floor Price to Stock Exchanges (Issued pursuant to a Notice for Offer for Sale of 37,49,950 equity shares of face value of Rs. 2 each of AstraZeneca Pharma India Limited by the promoter AstraZeneca Pharmaceuticals AB Sweden to the Stock Exchanges on May 24, 2013)

Pursuant to Clause 5(b) of circular number CIR/MRD/DP/18/2012 dated July 18, 2012, notified by the Securities and Exchange Board of India, as amended pursuant to the Circular CIR/MRD/DP/04/2013 dated January 25, 2013 (the “SEBI Circular”), AstraZeneca Pharmaceuticals AB Sweden (the “Seller”), proposes to sell an aggregate of 37,49,950 equity shares of face value of Rs. 2 each of AstraZeneca Pharma India Limited (the “Company”, and such equity shares referred to as “OFS Sale Shares”) on May 28, 2013, exclusively through the Seller’s broker ICICI Securities Limited through a sale on the separate window provided by BSE Limited (the “BSE”) and The National Stock Exchange of India Limited (the “NSE”, and together with the BSE, the “Stock Exchanges”) for this purpose under notice no. 20120222-34 dated February 22, 2012, notice no. 20120228-30 dated February 28, 2012, notice no. 20120727-26 dated July 27, 2012, and notice no. 20130129-23 dated January 29, 2013, issued by the BSE Limited and circular ref. no. 2/2012 dated February 21, 2012, circular ref. no. 73/2012 dated February 24, 2012 and circular ref. no. 52/2012 dated August 2, 2012, circular ref. no. 005/2013 dated January 30, 2013, circular ref. no. 0037/2013 dated January 31, 2013, issued by the National Stock Exchange of India Limited (the “Sale”).

The details of the Sale being made are in accordance with the SEBI Circular and other important information as set out in the notice dated May 24, 2013. Pursuant to Clause 5(c) of the SEBI Circular, the details of floor price, below which no orders in the Sale shall be considered, is set out below:

Rs. 490 (Rupees Four hundred and ninety only) per equity share of the Company (the “Floor Price”).

We request you to kindly disseminate the Floor Price to the market in accordance with the SEBI Circular.

For AstraZeneca Pharmaceuticals AB Sweden

Name: Mr. Jan-Olof Jacke
Designation: Director
Authorized Signatory